Disease · MONDO_0006047

pancreatic adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pancreatic adenocarcinoma. Diseases, record MONDO_0006047. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006047

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pancreatic adenocarcinoma; Open Targets
Open Targets ID: MONDO_0006047; Open Targets
Other names: adenocarcinoma - pancreas, adenocarcinoma of pancreas, adenocarcinoma of the pancreas, pancreas adenocarcinoma; Open Targets
Disease Ontology: DOID:4074; Disease Ontology
NCI Thesaurus: C8294; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 31 of its 265 drugs, from ClinicalTrials.gov; Open Targets

Drugs265

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	243	243	243	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	127	127	99	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	119	119	92	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	113	113	76	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 3	ClinicalTrials.gov	84	84	60	Drugs and targets
LEUCOVORIN	CHEMBL1679	Small molecule	Phase 3	ClinicalTrials.gov	61	61	37	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	37	37	36	Drugs and targets
GEMCITABINE HYDROCHLORIDE	CHEMBL1637	Small molecule	Phase 3	ClinicalTrials.gov	30	30	30	Drugs and targets
LEUCOVORIN CALCIUM	CHEMBL1201138	Small molecule	Phase 3	ClinicalTrials.gov	25	25	21	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	21	21	21	Drugs and targets

1 to 10 of 265

See all 265 drugs

Targets357

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	13	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
KDR	Vascular endothelial growth factor receptor	10	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
TUBA1A	Tubulin	10	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	10	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	10	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	10	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	10	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	10	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	10	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	10	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets

1 to 10 of 357

See all 357 targets

Trials498

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01928394	A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors	Phase 1/2	1,163	2020-03-24	Advanced or Metastatic Solid Tumors	COBIMETINIB, IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00844649	Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas	Phase 3	861	2013-12-11	Metastatic Pancreatic Cancer	GEMCITABINE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT01231347	QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas	Phase 3	800	2024-07-16	Adenocarcinoma of the Pancreas, Advanced Solid Tumors, Cancer, Cancer of Pancreas, Cancer of the Pancreas, Metastases, Metastatic Cancer, Metastatic Pancreatic Cancer, Pancreas Cancer, Pancreatic Cancer, Bone Metastases, Endocrine Cancer, Oncology, Oncology Patients, Solid Tumors, Advanced Malignancy	GANITUMAB, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT04083235	A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment	Phase 3	770	2024-03-13	Metastatic Adenocarcinoma of the Pancreas	FLUOROURACIL, IRINOTECAN, LEUCOVORIN CALCIUM, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT01746979	Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma	Phase 3	693	2017-12-02	Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma	EVOFOSFAMIDE, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT00471146	Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.	Phase 3	630	2012-07-16	Carcinoma, Pancreatic Ductal	AXITINIB, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT02923921	Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer	Phase 3	567	2020-10-19	Pancreatic Cancer	FLUOROURACIL, FOLINIC ACID, OXALIPLATIN, PEGILODECAKIN	Its record names the disease	ClinicalTrials.gov
NCT03504423	Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas	Phase 3	528	2023-01-03	Pancreatic Cancer Metastatic	CPI 613, FLUOROURACIL, IRINOTECAN HYDROCHLORIDE, LEUCOVORIN CALCIUM, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT03665441	Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC	Phase 3	512	2022-09-28	Pancreatic Adenocarcinoma	ASPARAGINASE, FLUOROURACIL, GEMCITABINE, IRINOTECAN, IRINOTECAN HYDROCHLORIDE, LEUCOVORIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT02436668	Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)	Phase 3	430	2020-11-16	Metastatic Pancreatic Adenocarcinoma	GEMCITABINE, IBRUTINIB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 498

See all 498 trials

Comparisons in its trials113

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Albumin-bound Paclitaxel (ABI-007)/Gemcitabine vs Gemcitabine: serious adverse events	212 of 421	172 of 402	823	NCT00844649	Trial comparisons
NALIRIFOX vs Nab-paclitaxel+Gemcitabine: deaths from any cause	345 of 370	359 of 379	749	NCT04083235	Trial comparisons
NALIRIFOX vs Nab-paclitaxel+Gemcitabine: serious adverse events	207 of 370	198 of 379	749	NCT04083235	Trial comparisons
TH-302 vs Placebo: serious adverse events	341 of 341	338 of 338	679	NCT01746979	Trial comparisons
Axitinib + Gemcitabine vs Placebo + Gemcitabine: serious adverse events	108 of 304	102 of 309	613	NCT00471146	Trial comparisons
Pegilodecakin + FOLFOX vs FOLFOX: deaths from any cause	217 of 278	188 of 251	529	NCT02923921	Trial comparisons
Pegilodecakin + FOLFOX vs FOLFOX: serious adverse events	123 of 278	95 of 251	529	NCT02923921	Trial comparisons
CPI-613, mFolfirinox vs Folfirinox: Overall Response Rate (ORR)	104 of 266	90 of 262	528	NCT03504423	Trial comparisons
Eryaspase Plus Chemotherapy vs Chemotherapy Alone: Disease Control Rate (DCR)	147 of 255	126 of 257	512	NCT03665441	Trial comparisons
Eryaspase Plus Chemotherapy vs Chemotherapy Alone: Objective Response Rate (ORR)	41 of 255	32 of 257	512	NCT03665441	Trial comparisons

1 to 10 of 113

See all 113 comparisons in its trials

Papers from its trials228

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40131728	RESULT	1	PubMed
38050737	RESULT	2	PubMed
37936126	RESULT	1	PubMed
37041522	RESULT	1	PubMed
36028483	RESULT	1	PubMed
35399603	RESULT	1	PubMed
34844976	RESULT	1	PubMed
34288696	RESULT	1	PubMed
33427657	RESULT	1	PubMed
33405269	RESULT	1	PubMed

1 to 10 of 228

See all 228 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006047

GET https://conductscience.org/api/diseases/v1/MONDO_0006047/drugs?page=2

API reference For AI assistants